Elite Pharmaceuticals, Inc.
ELTP
$0.37
$0.00-0.62%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.71% | 35.70% | 332.85% | -134.62% | 256.06% |
| Total Depreciation and Amortization | -2.98% | -0.76% | 0.55% | -2.34% | 6.31% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 30.31% | -93.36% | -119.28% | 746.04% | -135.42% |
| Change in Net Operating Assets | 80.80% | -268.62% | 45.72% | 24.25% | -263.95% |
| Cash from Operations | 273.28% | -203.41% | -65.46% | 277.13% | 468.34% |
| Capital Expenditure | -93.11% | -99.52% | 52.66% | 71.06% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -93.11% | -99.52% | 52.66% | 71.06% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 2.99% | 53.55% | 93.55% | -2,542.80% | 19.06% |
| Issuance of Common Stock | -12.97% | -39.87% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -23.51% | 71.16% | 97.18% | -2,915.11% | 29.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 257.79% | -212.97% | -53.16% | 244.48% | 340.84% |